Effect of chronic blood transfusion on biomarkers of coagulation activation and thrombin generation in sickle cell patients at risk for stroke

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Hyacinth, Hyacinth I ^a,b   Adams, Robert J ^b   Greenberg, Charles S ^c   Voeks, Jenifer H ^b   Hill, Allyson ^d   Hibbert, Jacqueline M ^e   Gee, Beatrice E ^e,f  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d Department of Teacher Education and Department of Sociology and Anthropology   (United States)

^e MOREHOUSE SCHOOL OF MEDICINE   (United States)

^f CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR; D DIMER; HEMOGLOBIN; THROMBIN; TRANSACTIVATOR PROTEIN; VON WILLEBRAND FACTOR; ANTITHROMBIN III; ANTITHROMBIN III-PROTEASE COMPLEX; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D; PEPTIDE HYDROLASE;

ARTICLE; BLOOD LEVEL; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CHILD; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SICKLE CELL ANEMIA; THERAPY EFFECT; TREATMENT RESPONSE; VELOCITY; BLOOD; BLOOD CLOTTING; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC IMAGING; METABOLISM; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; STROKE; TRANSCRANIAL DOPPLER ULTRASONOGRAPHY;

ANEMIA, SICKLE CELL; ANTITHROMBIN III; BIOMARKERS; BLOOD COAGULATION; BLOOD TRANSFUSION; CHILD; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; PEPTIDE HYDROLASES; RISK FACTORS; STROKE; THROMBIN; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL; VON WILLEBRAND FACTOR;

EID: 84942890597     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134193     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. Children with sickle cell disease had significantly higher medical costs than those without sickle cell disease. 2012;2012
2. Hassell KL. Population estimates of sickle cell disease in the U. S. Am J Prev Med 2010;38:S512-S521 doi: 10.1016/j.amepre.2009.12.022 PMID: 20331952
3. Smith LA, Oyeku SO, Homer C, Zuckerman B. Sickle cell disease: A question of equity and quality. Pediatrics 2006;117:1763-1770 PMID: 16651336
4. Weatherall DJ. Hemoglobinopathies worldwide: Present and future. Curr Mol Med 2008;8:592-299 PMID: 18991645
5. Pauling L, Itano HA. Sickle cell anemia a molecular disease. Science 1949;110:543-548 PMID: 15395398
6. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: A curious paradox. Am J Med 2003;115:721-728 PMID: 14693325
7. Ataga KI. Hypercoagulability and thrombotic complications in hemolytic anemias. Haematologica 2009;94:1481-1484 doi: 10.3324/haematol.2009.013672 PMID: 19880774
8. Ataga KI, Moore CG, Hillery CA, Jones S, Whinna HC, Strayhorn D, et al. Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension. Haematologica 2008;93:20-26 doi: 10.3324/haematol.11763 PMID: 18166781
9. Ataga KI, Brittain JE, Desai P, May R, Jones S, Delaney J, et al. Association of coagulation activation with clinical complications in sickle cell disease. PLoS ONE 2012;7:e29786 doi: 10.1371/journal. pone.0029786 PMID: 22253781
10. van Beers EJ, Schaap MCL, Berckmans RJ, Nieuwland R, Sturk A, van Doormaal FF, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009;94:1513-1519 doi: 10.3324/haematol.2009.008938 PMID: 19815831
11. Hyacinth HI, Gee BE, Adamkiewicz TV, Adams RJ, Kutlar A, Stiles JK, et al. Serum BDNF and PDGFAA levels are associated with high TCD velocity and stroke in children with sickle cell anemia. Cytokine 2012;60:302-308 doi: 10.1016/j.cyto.2012.05.017 PMID: 22704695
12. Hyacinth HI, Adams RJ, Voeks JH, Hibbert JM, Gee BE. Frequent red cell transfusions reduced vascular endothelial activation and thrombogenicity in children with sickle cell anemia and high stroke risk. Am J Hematol 2014;89:47-51 doi: 10.1002/ajh.23586 PMID: 23996496
13. Adams R, McKie V, Nichols F, Carl E, Zhang D-L, McKie K, et al. The use of transcranial ultrasonography to predict stroke in sickle cell disease. N Engl J Med 1992;326:605-610 PMID: 1734251
14. Dobson SR, Holden KR, Nietert PJ, Cure JK, Laver JH, Disco D, et al. Moyamoya syndrome in childhood sickle cell disease: A predictive factor for recurrent cerebrovascular events. Blood 2002;99:3144-3150 PMID: 11964276
15. Gebreyohanns M, Adams RJ. Sickle cell disease: Primary stroke prevention. CNS Spectrum. 2004;9:445-449
16. Hulbert ML, Scothorn DJ, Panepinto JA, Scott JP, Buchanan GR, Sarnaik S, et al. Exchange blood transfusion compared with simple transfusion for first overt stroke is associated with a lower risk of subsequent stroke: A retrospective cohort study of 137 children with sickle cell anemia. J Pediatr 2006;149:710-712 PMID: 17095350
17. Deane CR, Goss D, Bartram J, Pohl KRE, Height SE, Sibtain N, et al. Extracranial internal carotid arterial disease in children with sickle cell anemia. Haematologica 2010;95:1287-1292 doi: 10.3324/haematol.2010.022624 PMID: 20220066
18. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med 1998;339:5-11 PMID: 9647873
19. Ware RE, Helms RW, SWiTCH Investigators. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood 2012;119:3925-32. doi: 10.1182/blood-2011-11-392340 PMID: 22318199
20. Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 2005;353:2769-2778 PMID: 16382063
21. Hulbert ML, McKinstry RC, Lacey JL, Moran CJ, Panepinto JA, Thompson AA, et al. Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood 2011;117:772-779 doi: 10.1182/blood-2010-01-261123 PMID: 20940417
22. Asare K, Gee BE, Stiles JK, Wilson NO, Driss A, Quarshie A, et al. Serum interleukin-1β concentration is associated with stroke in sickle cell disease. Cytokine. 2010;49:39-44 doi: 10.1016/j.cyto.2009.10. 002 PMID: 19900820
23. Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009;84:618-625 doi: 10.1002/ajh.21475 PMID: 19610078
24. Merkel K, Ginsberg P, Parker J, Post M. Cerebrovascular disease in sickle cell anemia: A clinical, pathological and radiological correlation. Stroke 1978;9:45-52 PMID: 622745
25. Prohovnik I, Hurlet-Jensen A, Adams R, De Vivo D, Pavlakis SG. Hemodynamic etiology of elevated flow velocity and stroke in sickle-cell disease. J Cereb Blood Flow Metab 2009;29:803-810 doi: 10. 1038/jcbfm.2009.6 PMID: 19209182
26. Prohovnik I, Pavlakis SG, Piomelli S, Bello J, Mohr JP, Hilal S, et al. Cerebral hyperemia, stroke, and transfusion in sickle cell disease. Neurology 1989;39:344 PMID: 2927641
27. Jordan LC, Casella JF, DeBaun MR. Prospects for primary stroke prevention in children with sickle cell anaemia. Br J Haematol 2012;157:14-25 doi: 10.1111/j.1365-2141.2011.09005.x PMID: 22224940
28. Blann A, Kumar P, Krupinski J, McCollum C, Beevers DG, Lip GY. Soluble intercelluar adhesion molecule-1, e-selectin, vascular cell adhesion molecule-1 and von willebrand factor in stroke. Blood Coagul Fibrinolysis 1999;10:277-284 PMID: 10456619
29. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, et al. Fibrin d-dimer and coronary heart disease: Prospective study and meta-analysis. Circulation. 2001;103:2323-2327 PMID: 11352877
30. Colombatti R, De Bon E, Bertomoro A, Casonato A, Pontara E, Omenetto E, et al. Coagulation activation in children with sickle cell disease is associated with cerebral small vessel vasculopathy. PLoS ONE. 2013;8:e78801 doi: 10.1371/journal.pone.0078801 PMID: 24205317
31. Lezcano NE, Odo N, Kutlar A, Brambilla D, Adams RJ. Regular transfusion lowers serum free hemoglobin in children with sickle-cell disease at risk for stroke. Stroke. 2006;37:1424-1426 PMID: 16627796
32. Zhou Z, Han H, Cruz MA, Lopez JA, Dong JF, Guchhait P. Haemoglobin blocks von willebrand factor proteolysis by ADAMTS-13: A mechanism associated with sickle cell disease. Thromb Haemost 2009;101:1070-1077 PMID: 19492149
33. Whelihan MF, Zachary V, Orfeo T, Mann KG. Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation. Blood 2012;120:3837-3845. doi: 10.1182/blood-2012-05-427856 PMID: 22968460
34. Whelihan MF, Mooberry MJ, Zachary V, Bradford RL, Ataga KI, Mann KG, et al. The contribution of red blood cells to thrombin generation in sickle cell disease: meizothrombin generation on sickled red blood cells. J Thromb and Haemost 2013;11:2187-2189.
35. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997;89:1121-32. PMID: 9028933
36. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood 2001;98:3228-33. PMID: 11719358
37. Iversen LH, Thorlacius-Ussing O. Short-time stability of markers of coagulation and fibrinolysis in frozen serum. Thrombo Res 81:253-261
38. Woodhams B, Girardot O, Blanco MJ, Colesse G, Gourmelin Y. Stability of coagulation proteins in frozen serum. Blood Coagul Fibrinolysis. 2001;12:229-236 PMID: 11460005